EUVIMEDEUVIMED entdecken
Crossref

Modern diagnostics and treatment of Merkel cell carcinoma

Juliane Weilandt, Wiebke K Peitsch

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2023-12 · 21 (12) · 1524-1546

DOI: 10.1111/ddg.15214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, online erschienen am 24.10.2023. Verfasst von Juliane Weilandt und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Phlebology, Vivantes Klinikum im Friedrichshain, Berlin, Germany. Hauptthemen laut MEDLINE: Carcinoma, Merkel Cell, Skin Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 176 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Merkel cell carcinoma (MCC) is a rare, aggressive skin cancer with epithelial and neuroendocrine differentiation, the incidence of which has increased substantially during the last decades. Risk factors include advanced age, fair skin type, UV exposure, and immunosuppression. Pathogenetically, a type caused by the Merkel cell polyomavirus is distinguished from a UV‐induced type with a high tumor mutational burden. Clinically, MCC presents as a mostly painless, rapidly growing, reddish‐violet tumor with a shiny surface, which is preferentially localized in the head‐neck region and at the distal extremities. A reliable diagnosis can only be made based on histological and immunohistochemical features. At initial diagnosis, 20–26% of patients show locoregional metastases and 8–14% distant metastases, making staging examinations indispensable. If there is no clinical evidence of metastases, a sentinel lymph node biopsy is recommended. Essential columns of therapy are surgery, adjuvant or palliative radiotherapy and, in advanced inoperable stages, medicamentous tumor therapy. The introduction of immune checkpoint inhibitors has led to a paradigm shift, as they provide a considerably longer duration of response and better survival rates than chemotherapy. The PD‐L1 inhibitor avelumab is approved for treatment of metastatic MCC in Germany, but the PD‐1 antibodies pembrolizumab and nivolumab are also used with success. Adjuvant and neoadjuvant treatment concepts, immune combination therapies and targeted therapies as monotherapy or in combination with immune checkpoint inhibitors are in the clinical trial phase.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Merkel CellSkin NeoplasmsHumansImmune Checkpoint InhibitorsCombined Modality TherapyNivolumab

Stichwörter der Autor:innen

Merkel cell carcinomaMerkel cell polyomavirusavelumabimmune checkpoint inhibitorsnivolumabpembrolizumab

Substanzen

Immune Checkpoint InhibitorsNivolumab

Autor:innen und Institutionen

  • Department of Dermatology and Phlebology, Vivantes Klinikum im Friedrichshain, Berlin, Germany.

Zitieren

APA

Weilandt, J., & Peitsch, W. K. (2023). Modern diagnostics and treatment of Merkel cell carcinoma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 21(12), 1524-1546. https://doi.org/10.1111/ddg.15214

Vancouver

Weilandt J, Peitsch WK. Modern diagnostics and treatment of Merkel cell carcinoma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2023;21(12):1524-1546. doi:10.1111/ddg.15214

BibTeX
@article{Weilandt2023,
  author = {Weilandt, Juliane and Peitsch, Wiebke K},
  title = {Modern diagnostics and treatment of Merkel cell carcinoma},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2023},
  volume = {21},
  number = {12},
  pages = {1524--1546},
  doi = {10.1111/ddg.15214}
}
Kostenlos starten →